ResearcherIran University of Medical SciencesActive in the last 2 years

Fatemeh Aliabadi

ORCID-verified (high confidence)As of 12 November 2026

Matched on ORCID iD 0009-0002-2669-2749; OpenAlex author ID A5079767501.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 2 (first author 0, last author 1)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 2

Papers, trials and grants by year

2025: 2 papers

Papers 2

Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma. Co-author DOI 10.1098/rsob.240412 ↗
Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma. Last author DOI 10.34172/bi.29993 ↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Bahareh Shateri Amiri · 2 shared papers, 2025
- Paper Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma. DOI 10.1098/rsob.240412 ↗
- Paper Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma. DOI 10.34172/bi.29993 ↗
Lina Hejrati · 2 shared papers, 2025
- Paper Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma. DOI 10.1098/rsob.240412 ↗
- Paper Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma. DOI 10.34172/bi.29993 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.